Key Points
- Kestra Medical Technologies CFO Vaseem Mahboob sold 39,903 shares at an average price of $30.48, generating approximately $1.22 million and reducing his direct ownership by 39.7% to 60,609 shares.
- Mahboob has made several additional sales recently, including 34,809 shares on October 27 and 4,788 shares on October 29, alongside multiple sales during July and August.
- KMTS shares opened at $30.61, near their 52-week high of $31.04. Analysts hold a consensus “Moderate Buy” rating with an average $29 price target, while the company continues to report losses and missed its latest earnings estimate.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) CFO Vaseem Mahboob sold 4,788 shares of the business's stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $30.60, for a total value of $146,512.80. Following the sale, the chief financial officer owned 60,609 shares of the company's stock, valued at approximately $1,854,635.40. The trade was a 7.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Vaseem Mahboob also recently made the following trade(s):
- On Tuesday, October 27th, Vaseem Mahboob sold 34,809 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $30.04, for a total value of $1,045,662.36.
- On Wednesday, October 28th, Vaseem Mahboob sold 39,903 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $30.48, for a total value of $1,216,243.44.
- On Friday, August 7th, Vaseem Mahboob sold 26,287 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $25.88, for a total value of $680,307.56.
- On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $24.68, for a total value of $172,636.60.
- On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total value of $128,305.80.
- On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total transaction of $199,352.37.
Kestra Medical Technologies Price Performance
Kestra Medical Technologies stock opened at $30.61 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.69 and a current ratio of 4.69. Kestra Medical Technologies, Ltd. has a 1 year low of $17.34 and a 1 year high of $31.04. The company's 50-day moving average is $26.64 and its two-hundred day moving average is $23.79.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its quarterly earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. The business had revenue of $30.97 million for the quarter. As a group, research analysts expect that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages have issued reports on KMTS. Evercore initiated coverage on shares of Kestra Medical Technologies in a research note on Tuesday, October 20th. They issued an "outperform" rating and a $34.00 price objective on the stock. Oppenheimer started coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a "market perform" rating for the company. BTIG Research reissued a "buy" rating and issued a $32.00 price target on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Piper Sandler restated an "overweight" rating on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Finally, Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a research note on Wednesday, July 15th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $29.00.
Read Our Latest Report on KMTS
Institutional Trading of Kestra Medical Technologies
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Sterling Capital Management LLC raised its position in shares of Kestra Medical Technologies by 834.0% in the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company's stock valued at $25,000 after acquiring an additional 784 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Kestra Medical Technologies by 6.6% during the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company's stock worth $1,844,000 after acquiring an additional 5,731 shares during the last quarter. California State Teachers Retirement System boosted its stake in Kestra Medical Technologies by 39.2% during the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company's stock worth $555,000 after acquiring an additional 7,844 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Kestra Medical Technologies during the third quarter valued at approximately $353,000. Finally, Quantinno Capital Management LP acquired a new position in Kestra Medical Technologies during the first quarter valued at approximately $431,000.
Kestra Medical Technologies Company Profile
(
Get Free Report)
Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient's heart rhythm and deliver a therapeutic shock when clinically necessary.
The company's platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
